Publication | Open Access

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

Drug SafetyHematological MalignancyOncologyDoxorubicin-treated ChildrenPediatric HematologyPatient SafetyPharmacologyPediatricsHematologyPharmacotherapyMedicineLong-term Follow-up